9. Solid lipid nanoparticles for kidney targeting

In order to overcome these limitations acid treated montmorillonite (Mt)- Betaxolol Hydrochloride (BH) nanocomposite encapsulated SLNs (Mt-BH-SLNs) were developed. An acid-treated montmorillonite (acid-Mt) was first intercalated with BH in the interlayers and this nanocomposite was encapsulated by SLNs. The developed Mt-BH-SLNs possess good stability. Long term irritation test reported that the (Mt-BH-SLNs) showed no damage for cornea and conjunctiva. The corneal hydration level of Mt-BH-SLNs was higher (78.25 0.63)% indicating higher drug corneal permeability and absence of irritation to the cornea. Thus, Mt-BH-SLNs

7.2.3 Polyethylene glycol (PEG) conjugated (PEGylated) solid lipid nanoparticles

for 12 months. Thus it could be helpful in the treatment of keratitis and

8. Solid lipid nanoparticles for passive colon targeting

endophthalmitis [73].

been summarized in Table 5.

molecular imaging simultaneously [75].

been summarized in Table 5.

114

Ketoconazole (KTZ) is a broad spectrum antifungal agent, with high liposolubility [71] but a short ocular half-life (elimination half-life is 19 min in

aqueous humor and 43 min in cornea) [72] and very poor solubility (0.04 mg/ml). Ketoconazole (KTZ) loaded PEGylated SLNs were developed for targeted delivery of KTZ to the posterior part of the eye for treatment of fungal infection. It showed higher bioavailability both in the aqueous and vitreous humor with significant antifungal potential. The ex vivo corneal permeation study revealed higher corneal permeability of the PEGylated KTZ-SLNs. The developed SLN was satisfying various parameters suitable for ocular delivery such as pH, osmolarity, stability, autoclavability, particle size, preservation against contamination. The SLNs were found to be stable in terms of entrapment efficiency and total drug content at 2–8°C

List of SLNs and their different ligand conjugated forms for eye targeting have

Combination of nanocarriers and electroporation techniques is named as electropermeabilization which is commonly used for enhancing drug transport. The Cyanine–type IR 780 and Baicalein (BAI) co-encapsulated SLNs were developed for both imaging and therapy of colorectal carcinoma where cyanine–type IR 780 and baicalein (flavonoid derivative) were acting as a diagnostic agent (photosensitizer) and therapeutic cargo respectively. For preparation of SLNs the organic phase was prepared by dissolving IR-780, BAI, and melted lipid in dichloromethane. The organic phase was then added dropwise to hot aqueous phase containing surfactant under vigorous stirring. Supplementary material (flavonoids) facilitated in the reduction of dose and reduction in normal cell toxicity in cancer chemotherapy. The external electric field pulses applied in electroporation helped in increased of cell membrane permeability, either by generating transient pores or membrane electropermeabilization [74]. Electropermeabilization mediated administration of the developed SLNs showed cytoskeletal abnormalities more significantly then without electropermeabilization. The prepared SLNs particles were with good physical stability. With electroporation support, the developed SLNs showed increased p53 and manganese superoxide dismutase expression with significant higher cytotoxicity, thus validating their suitability for combined therapy and

List of SLNs and their different ligand conjugated form for colon targeting have

could be used for effective management of glaucoma [70].

Role of Novel Drug Delivery Vehicles in Nanobiomedicine

## 9.1 Solid lipid nanoparticles for passive kidney targeting
